NCT00143429

Brief Summary

Compare the antihypertensive efficacy of three methods for installing Xalatan

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 1, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 2, 2005

Completed
Last Updated

February 2, 2021

Status Verified

March 1, 2015

First QC Date

September 1, 2005

Last Update Submit

February 1, 2021

Conditions

Glaucoma, Open-AngleOcular Hypertension

Keywords

Primary Open Angle Glaucoma

Outcome Measures

Primary Outcomes (1)

  • IOP level in the study eye

Secondary Outcomes (1)

  • Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period

Interventions

XalatanDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

You may not qualify if:

  • History of closed/barely open anterior chamber angle or a history of angle closure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

Latanoprost

Condition Hierarchy (Ancestors)

GlaucomaEye Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins F, SyntheticProstaglandins, SyntheticProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 1, 2005

First Posted

September 2, 2005

Last Updated

February 2, 2021

Record last verified: 2015-03